| Bioactivity | Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide. | ||||||
| Invitro | A cell-cell fusion assay reveals that the effective concentration for achieving 50% inhibition (IC50) of Enfuvirtide is 23 ± 6 nM[2]. IFN-λs (1, 2, or 3) or the antiretrovirals (AZT, Efavirenz, Indinavir, and Enfuvirtide) significantly inhibita the expression of HIV p24 antigen and Gag gene in macrophages. IFN-λs (1, 2, or 3) also enhanced the anti-HIV (Bal) effect of AZT, Efavirenz, Indinavir, and Enfuvirtide[3]. | ||||||
| Name | Enfuvirtide | ||||||
| CAS | 159519-65-0 | ||||||
| Sequence | Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 | ||||||
| Shortening | Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2 | ||||||
| Formula | C204H301N51O64 | ||||||
| Molar Mass | 4491.88 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |